L
H IS A HETERODIMERIC glycoprotein consisting of a unique ␤-subunit and a common ␣-subunit that is also shared by FSH, thyroid-stimulating hormone, and chorionic gonadotropin (1) (2) (3) (4) . LH is synthesized in anterior pituitary gonadotrope cells in which it is regulated by GnRH. Because the LH ␤-subunit is present at lower levels than the ␣-subunit, the concentration of LH ␤-subunit is the limiting factor in LH synthesis and secretion (5) . Thus, understanding the regulation of the LH␤ gene by GnRH is key to understanding the synthesis and secretion of LH.
GnRH is synthesized by hypothalamic neurons and delivered through the hypophyseal portal system to the pituitary in a pulsatile fashion. The intermittent pattern of release is critical for normal sexual development and gametogenesis because interruption of GnRH pulses or administration of long-acting GnRH analogs and antagonists result in suppression of both gonadotropin and gonadal steroid production, resulting in infertility (6) . Specifically, GnRH pulsatility is essential for induction of LH␤ gene expression because continuous incubation for 24 h with GnRH leads to desensitization of GnRH receptors (GnRH-Rs) and downregulation of LH ␤-subunit mRNA, although not ␣-subunit mRNA (7, 8) .
GnRH acts on gonadotropin gene expression through the GnRH-R, a G protein-coupled receptor that activates several signal transduction pathways (9, 10) . This receptor activates L-type calcium channels, causing an influx of extracellular calcium (11, 12) , and also activates phospholipase C (PLC). PLC cleaves phosphatidylinositoldiphosphate located in the cell membrane into inositol triphosphate, which mediates the calcium release from intracellular stores, and produces diacylglycerol (DAG) (13) . Increased concentrations of intracellular calcium together with DAG, lead to activation of protein kinase C (PKC), which, in turn, activates other proteins by phosphorylation. This generally results in activation of downstream protein kinases such as those of the MAPK pathway (13, 14) . The increase in calcium concentration in the cytoplasm can also activate other protein kinases such as the c-Jun N-terminal kinase (15, 16) independently of PKC or other members of the MAPK family. In addition, there are examples in other G protein-coupled receptor signaling systems in which nuclear calcium may change gene expression independently from cytoplasmic calcium (17, 18) .
Incoming GnRH signals acting through this single receptor differentially regulate the gonadotropin subunit genes during the estrous cycle and in a variety of pharmacologic and pathophysiologic conditions. Differences in GnRH pulse frequency and/or receptor density allow gonadotrope cells to differentially activate LH vs. FSH synthesis (19 -22) , likely Abbreviations: AP-1, Activator protein-1; BMM, bisindolylmaleimide I hydrochloride; CAT, chloramphenicol acetyl transferase; DAG, diacylglycerol; eLH, equine LH; GnRH-R, GnRH receptor; hLH, human LH; PKC, protein kinase C; PLC, phospholipase C; rLH, rat LH; SF-1, steroidogenic factor-1; TK, thymidine kinase; TPA, 12-O-tetradecanoylphorbol-13-acetate; VLH, variant LH.
caused by differential activation of downstream signaling pathways. It is thought that signaling pathways regulating the ␣-subunit gene are distinct from those activating the LH ␤-subunit gene (23) . Moreover, it is possible that GnRH-R activation of different signal transduction pathways is involved in acute induction vs. chronic repression of LH␤ gene expression. There are several reports regarding regulation of ␣ and LH␤ mRNAs by GnRH, but the results of these studies differ as to the effects of various GnRH time courses, concentrations, and the signal transduction pathways involved. Some studies report that GnRH or other GnRH-R agonists are capable of decreasing LH␤ mRNA after 24-h incubation (7, 8, 24, 25) . Other studies show either increased or unchanged levels of LH␤ mRNA by GnRH-R agonists (26, 27) . All of these studies, however, agree that there is no downregulation of the ␣-subunit after 24-h incubation with GnRH.
Until recently, there was no ideal cell model for studying the regulation of LH␤ gene expression by GnRH. In primary pituitary cultures and in vivo systems, the influence of other cell types and paracrine interactions can interfere with the effect of GnRH on pituitary gonadotropes (28, 29) . In addition, these complex cultures do not allow direct quantification of signal cascades in response to GnRH in the gonadotropes because these cells compose only 5-10% of the cells in the pituitary (5, 30) . Cell lines such as GGH 3 and ␣T3-1 have also been used as models for GnRH action (31) (32) (33) (34) . The GGH 3 cell line consists of rat somatomammotropic tumor cells (GH 3 ) stably transfected with an expression vector for GnRH-R (33, 35) . It is likely that the heterologous cellular environment causes coupling to signaling components not normally used or even present in gonadotropes (35) . For example, GnRH-R couples to cAMP in GGH 3 cells (35), a signaling pathway not activated in the ␣T3-1 gonadotropelineage cell line (34) . Furthermore, GGH 3 cells do not express steroidogenic factor-1 (SF-1), an important activator of gonadotrope-specific genes that is thought to interact with EGR-1 (NGFI-A), an early response gene that is induced by GnRH and is also important for LH␤ gene expression (36 -41) . In the GGH 3 system, transcription from the LH␤ promoter is activated by PKC, and transcription from the ␣-subunit promoter is activated by calcium (32, 42) .
␣T3-1 cells are immortalized mouse pituitary tumor cells belonging to the gonadotrope lineage. These cells express the glycoprotein hormone ␣-subunit, GnRH-R and SF-1, but they are derived from an early stage of pituitary development when LH␤ is not yet expressed, and these cells therefore do not naturally express LH␤ (43, 44) . To circumvent this deficiency, Weck et al. (23) employed a chimeric reporter gene consisting of Ϫ617 to Ϫ245 of the LH␤ gene placed upstream of the thymidine kinase (TK) promoter in transfections of ␣T3-1 cells. Because SF-1 and EGR-1 are bound to a more proximal region of the LH␤ promoter (36, 45) and EGR-1 can be regulated by signaling pathways, this reporter gene does not fully address the regulation of LH␤ by GnRH. Nevertheless, it was shown that transcriptional activation through this LH␤ promoter fragment is induced by calcium, and the transcription of the ␣-subunit gene is activated by PKC. These data directly oppose those obtained using GGH 3 cells, described above. Thus, a more homologous gonadotrope cell model was needed to address these contradictions.
We have developed an immortalized LH-secreting gonadotrope, the L␤T4 cell line, by the method of targeted tumorigenesis in transgenic mice (46) . These cells express GnRH-R, SF-1, and the ␣ and ␤-subunits of LH (43) . A second cell line, L␤T2, cloned in the same manner from the same line of transgenic mice, was also shown to release LH in response to pulsatile GnRH (47, 48) and express FSH␤ (49, 50) . Therefore, the L␤T cell lines are valuable gonadotrope cell models for the study of LH regulation by GnRH.
In the current study, we have addressed the mechanisms by which the LH ␤-subunit gene is regulated by GnRH. We show that short-term incubation (6 h) of L␤T4 immortalized pituitary gonadotrope cells with GnRH leads to induction of LH␤ transcription, whereas continuous long-term incubation (24 h) leads to repression of LH␤ transcription. We also show that acute induction is mediated by the PKC signal transduction pathway, and long-term repression is mediated by the calcium signal transduction pathway. Not only do short-vs. long-term GnRH treatments act through different signaling systems; they also act through different elements on the rat LH␤ gene. Activation localizes to the upstream region (Ϫ451 to Ϫ384) that contains SP-1 and CArG elements (31, 51, 52) , and repression localizes to an evolutionarily conserved element found between Ϫ153 and Ϫ143. We conclude that the interaction of these two signal transduction pathways may function to balance the level of LH␤ mRNA synthesis and perhaps modulate levels throughout the estrous cycle.
Materials and Methods

Cells, media, and transfection protocols
L␤T4 cells were cultured in 80-cm 2 flasks and passed weekly by trypsin dispersion. The cells were maintained in DMEM (Life Technologies, Inc., Grand Island, NY) with 4.5 mg/ml glucose, 10% fetal bovine serum, and penicillin/streptomycin and maintained at 37 C with 5% CO 2 . All of the transfections were performed using the calcium phosphate precipitation method unless noted otherwise. For the calcium phosphate precipitation method, on the first day of the experiment, confluent flasks were split into 100-mm 2 tissue culture plates (one flask to eight plates). On the next day, the cells were transfected for 16 h with 15 g/plate reporter gene and 5 g/plate internal control TK-chloramphenicol acetyl transferase (CAT) plasmid. On the morning of the next day, the cells were subjected to glycerol shock (5 ml 10% glycerol in 1ϫ PBS per plate for 80 -90 sec) and then washed two times with 1ϫ PBS. For the transfections performed using FuGENE 6 transfection reagent (Roche Molecular Biochemicals Corp., Indianapolis, IN), 3 g reporter plasmid, and 1 g internal control were used, following the manufacturer's protocol. One day following the transfection, appropriate compounds were added in fresh medium. Cells were harvested either 6 h or 24 h later, as indicated. Protein extracts were prepared by freeze thawing as described (53) . CAT and luciferase assays were performed as previously described (54, 55) , and the luciferase activity of each sample was normalized to the internal control CAT activity.
Reagents
Ionomycin (0.5 m), 12-O-tetradecanoyl-phorbol-13-acetate (TPA) (100 nm), EGTA (2 mm), and GnRH agonist (des-Glu10,[d-Ala6]-LHRH ethylamide, 0.1, 1, 10, or 100 nm) were purchased from Sigma (St. Louis, MO). Bisindolylmaleimide I hydrochloride (BMM; 100 nm) and U0126 (750 nm) were purchased from Calbiochem (La Jolla, CA).
Plasmids
The LH␤-luciferase plasmid was prepared by fusing 1.8 kb of the rat LH␤ gene 5Ј flanking sequence into the HindIII restriction site of the pUC18 plasmid containing the luciferase gene (49) . The TK-CAT plas-mid contains Ϫ109 to ϩ55 of the TK promoter (derived from pBL-CATII) driving the CAT reporter gene (56) .
The Ϫ451 and Ϫ384 truncations of the LH ␤-subunit promoter were created by amplifying fragments from Ϫ451 or Ϫ384 to Ϫ216 by PCR, digesting the PCR products with HindIII and NheI, and then subcloning the 190-or 130-bp fragment into Ϫ1800LH␤Luc plasmid digested with HindIII and NheI. The forward primers for the PCR were 5Ј-CCGTA-CAAGCTTACCACACCCATTTTTGGACCCAAT-3Ј and 5Ј-CCGTG-CAAGCTTCTCTGGTTGTATTTAAAGCAAATT-3Ј for the Ϫ451 and Ϫ384 truncations, respectively. The reverse primer corresponds to the reverse DNA strand of the LH␤ promoter from Ϫ240 to Ϫ216.
The truncations containing 146, 179 nucleotides of LH␤ promoter or 179 nucleotides of LH␤ promoter with the mutation in the putative activator protein-1 (AP-1) site were created by subcloning the synthetic oligonucleotides corresponding to the regions of the LH␤ promoter from Ϫ146 to Ϫ121 or Ϫ179 to Ϫ121 (with added HindIII and native Tth111I half-sites) into the Ϫ1800LH␤Luc plasmid digested with HindIII and Tth111I.
EMSA assays
Annealed oligonucleotides (20 ng) containing sequences of rat, human, human variant, or equine LH␤ promoter were radiolabeled with ␥ [ 32 P]dATP (3000 Ci/mmol, NEN Life Science Products, Boston, MA) using the polynucleotide kinase method (57) . Probes were purified by passing through the G-50 microcolumns (Pharmacia Biotech, Piscataway, NJ), counted in a scintillation counter, and then diluted to 1 fmol/l in water. Binding reactions were carried out in 5 mm HEPES (pH 7.8), 30 mm KCl, 1 mm EDTA, 5 mm spermidine, 5 mm dithiothreitol, 0.2 mg/ml bovine serum albumin, 5 mm polydeoxyinosinic-deoxycytidylic acid, 10% (vol/ vol) glycerol, and 20 mg/ml Ficoll; 3 fmol of each probe were incubated with 2 g crude nuclear extract in 40-l reactions. Reactions were incubated at room temperature for 1 h and loaded into a 5% polyacrylamide gel (30:1 acrylamide/bisacrylamide, 0.25ϫ modified Tris-borate EDTA) and electrophoresed for 2 h at 225 V. Gels were prerun for 15-30 min in 0.25ϫ Tris-borate EDTA. After electrophoresis, gels were dried and subjected to autoradiography. Competition reactions were performed by mixing of radiolabeled probe and the specified amount of unlabeled oligonucleotide, and then adding the nuclear extract. Sequences are shown (see Figs. 9A and 10A) with the exception of the AP-1 consensus oligonucleotide, which has the sequence 5Ј-CTAGTGATGAGTCAGCCGGATC-3Ј. Oligonucleotides used in the EMSAs were obtained from Operon Technologies Inc. (Alameda, CA).
Western blotting
L␤T4 cells were grown to confluence in six-well plates, washed once with PBS, and incubated in serum-free DMEM overnight. For inhibition experiments, the cells were pretreated with U0126 (720 nm) for 30 min at 37 C. Cells were stimulated with increasing concentrations of GnRH (1, 10, 100 nm) for 5 min at 37 C. Thereafter cells were washed with ice-cold PBS and then lysed on ice in sodium dodecyl sulfate sample buffer (50 mm Tris, 5% glycerol, 2% sodium dodecyl sulfate, 0.005% bromophenol blue, 84 mm dithiothreitol, 100 mm sodium fluoride, 10 mm sodium pyrophosphate, and 2 mm sodium orthovanadate, pH 6.8), boiled for 5 min to denature proteins, and sonicated for 5 min to shear the chromosomal DNA. Equal volumes (30 -40 l) of these lysates were separated by SDS-PAGE on 10% gels and electrotransferred to polyvinylidene difluoride membranes (Immobilon-P, Millipore Corp., Bedford, MA). The membranes were blocked with 5% BSA in Tris-buffered saline-Tween [50 mm Tris-HCl (pH 7.4), 150 mm NaCl, 0.1% Tween-20]. Blots were incubated with primary anti-ACTIVE MAPK antibodies (Promega Corp., Madison, WI) at a dilution of 1:2500 in blocking buffer for 60 min at room temperature and then incubated with horseradish peroxidase-linked secondary antibodies followed by chemiluminescent detection. The polyvinylidene difluoride membranes were immediately stripped by placing the membrane in stripping buffer (0.5 m NaCl and 0.5 m acetic acid) for 10 min at room temperature. The membrane was then washed once for 10 min in Tris-buffered saline-Tween, reblocked, and blotted with antibodies to the unphosphorylated form of the ERK2 enzyme to control for equal protein loading.
Statistical analysis
All values are expressed as ratios of luciferase activity to CAT activity. Differences between groups were examined by ANOVA and post hoc testing using Fisher's protected least significant difference using the Statview program (SAS Institute, Inc., Cary, NC). Significant differences were declared for group comparisons returning an ␣ Յ 0.05.
Results
Acute GnRH treatment induced, but long-term GnRH treatment repressed, LH␤ transcription
Previous studies of the effects of GnRH on gene expression have generally used 6-h incubations with 10 nm GnRH agonist (23, 32) . Our first goal was to find the optimal GnRH dose for regulation of the Ϫ1800-bp rat LH␤ promoter on luciferase transfected into L␤T4 cells. As shown in Fig. 1A , 1 nm GnRH increased luciferase activity to 150%, and 10 nm GnRH increased luciferase activity to 160%, compared with untreated cells. To determine the optimal GnRH concentra- tion for long-term repression of LH␤ gene expression, transfected L␤T4 cells were incubated with increasing concentrations of a GnRH agonist for 24 h. LH␤-luciferase is repressed in a pattern inversely correlated with dose. Addition of 100 nm GnRH agonist does not lead to changes in luciferase activity, compared with control. Incubation with 10 nm GnRH agonist resulted in a small decrease in luciferase activity to 78% of control. Incubation with 1 nm GnRH resulted in decreased luciferase activity to approximately 50% of control (Fig. 1B) , although 0.1 nm has no statistically significant effect. All further studies used 10 nm GnRH agonist for acute treatments (6 h) and 1 nm GnRH agonist for long-term treatments (24 h).
Of note, a receptor for a related hormone, GnRH II, has been identified in primate gonadotropes (58, 59). It is unlikely that this novel receptor is activated by our treatments though because it exhibits a 40-fold preference for GnRH II, a hormone related to GnRH but not identical. The IC 50 for GnRH on the primate GnRH II receptor is 42 nm as opposed to that for GnRH II, which is 1 nm (59), and our studies use 1-10 nm GnRH.
Acute GnRH induction of LH␤ gene expression was reproduced by activation of PKC, and long-term GnRH repression was reproduced by inducing calcium influx
To determine whether induction of LH␤ gene expression by GnRH could be mimicked by an influx of calcium or activation of PKC, we incubated transfected L␤T4 cells with 0.5 m ionomycin or 100 nm of the phorbol ester TPA, an activator of PKC, for 6 h ( Fig. 2A) . Incubation with TPA resulted in an induction of the LH␤ promoter similar to that caused by 1 nm GnRH agonist. Incubation with ionomycin did not cause any significant change from control values ( Fig.  2A ) nor did treatment with 1 m thapsigargin, an agent that releases intracellular stores of calcium (data not shown).
If the long-term repression caused by GnRH is mediated through calcium or PKC, then agents that increase the intracellular calcium concentration or activate PKC should also repress LH␤-luciferase in long-term treatments. Incubation with TPA or ionomycin (or thapsigargin, data not shown) for 24 h at the doses used in the previous experiment also produced repression of LH␤-luciferase (Fig. 2B) . The magnitude of the repression was similar to that produced by 1 nm GnRH agonist. Thus, TPA mimics the biphasic regulation of the LH␤ gene produced by GnRH, and calcium influx reproduces only the later repressive phase.
Acute GnRH induction of LH␤ gene expression was prevented by blockade of PKC, and long-term repression was prevented by removal of extracellular calcium
To further assess the importance of the signal transduction pathway activated by calcium after 6-h incubation with GnRH, we used the calcium chelator EGTA. Treatment with EGTA alone did not result in significant changes, compared with the untreated cells or ionomycin-treated cells. As shown above ( Fig. 2A) , treatments with GnRH agonist or TPA (but not with ionomycin) led to induction of LH␤-luciferase activity. However, rather than blocking the induction, inclusion of EGTA with GnRH agonist or TPA produced statistically significant increases in luciferase activity, compared with untreated cells, cells treated with GnRH agonist alone, or TPA alone, respectively (Fig. 3A) . This result may indicate that GnRH-R activation of calcium influx is exerting downward pressure on LH␤ gene expression at the early time point (6 h) but that this repression is overcome by the stronger induction because of activation of PKC. This interpretation is supported by the observation that in the absence of calcium, induction by GnRH or TPA is more pronounced.
If the repression of LH␤ transcription by GnRH after the 24-h treatment is indeed mediated by calcium, removal of the calcium source should abolish the repression of LH␤ caused by the GnRH agonist. As in the previous experiment, cells were pretreated with EGTA and then cotreated with or without GnRH agonist, ionomycin, or TPA, but the time was increased to 24 h. Treatment with the GnRH agonist, ionomycin, or TPA resulted in statistically significant repression of luciferase activity, compared with control (Fig. 2B) . Pretreatment of transfected L␤T4 cells with EGTA reversed the effects of the GnRH agonist under these conditions without causing changes in LH␤ expression alone (Fig. 3B) , indicating a key role for calcium influx in GnRH repression of the LH␤ gene. Pretreatment with EGTA also partially reversed the repression because of ionomycin or TPA, indicating participation of the calcium signal cascade in repression by these treatments as well. The partial EGTA blockade may have been caused by utilization of insufficient concentrations to prevent the effect of ionomycin (although this level of EGTA is sufficient to block GnRH action). However, the cells do not tolerate higher levels of EGTA for 24 h.
If the induction of LH␤ gene expression by acute GnRH treatment is indeed mediated through the PKC signal transduction system, then inhibition of this system should block the effect of GnRH. As before ( Fig. 2A) , 6-h treatment with GnRH or TPA, but not with ionomycin, produced significant induction in LH␤ gene expression. As shown in Fig. 4A , the PKC inhibitor BMM blocked activation by GnRH or TPA, demonstrating a requirement for PKC action in GnRH induction of LH␤ gene expression. Moreover, although BMM alone did not affect LH␤ gene expression, it reduced LH␤ gene expression in combination with ionomycin, indicating again that the calcium-activated signal transduction pathway was capable of repressing expression at 6 h of incubation with GnRH. However, PKC activity apparently masked the repression by the calcium system, thus preventing observation of repression without blockade of PKC activity.
In Fig. 4B , cells incubated with GnRH agonist, ionomycin, or TPA in the absence of BMM for 24 h showed decreased luciferase activity as was observed in Fig. 2B . Treatment with BMM alone for 24 h did not lead to significant changes in luciferase activity, compared with untreated cells. However, although BMM prevented repression by TPA as expected, it did not prevent repression by GnRH agonist or ionomycin, indicating that long-term repression of LH␤ gene expression by GnRH is independent of the PKC signaling system.
The MAPK pathway is not involved in either short-term induction or long-term repression of the LH␤ promoter
One of the possible candidates acting downstream of the PKC or calcium systems to induce or repress the LH␤ promoter is the MAPK pathway. This pathway is active in gonadotropes and can be regulated by both the PKC and calcium systems independently from each other (11) (12) (13) . In our experiments, coincubation of GnRH agonist or TPA with the MEK inhibitor U0126 (final concentration 750 nm) for 6 h or coincubation of GnRH agonist or ionomycin with U0126 for 24 h did not lead to any significant changes in luciferase activity, compared with the groups treated by GnRH agonist, ionomycin, or TPA without U0126 (Fig. 5, A and B) . Under similar conditions, U0126 did block GnRH induction of control genes (data not shown). Therefore, we conclude that although the MAPK pathway is activated by GnRH and U0126 blocks this activation (Fig. 5C ), the MAPK pathway is not required for either short-term induction or long-term repression of LH␤ promoter by GnRH.
Acute induction and long-term repression use different regions of the LH␤ promoter
To further support our finding that calcium and PKC act through different, though interacting, pathways, we performed analysis of 5Ј truncations of the LH␤ promoter. If calcium and PKC indeed act through different pathways, they might exert their effects through different regions of the LH␤ promoter. Truncation of the LH␤ promoter sequence to Ϫ451 upstream of the transcription site did not disrupt responsiveness to incubation with GnRH agonist or TPA for 6 h (Ϫ1800 and Ϫ451), but truncation to Ϫ384 eliminated induction (Fig. 6A) . In contrast, a promoter truncated to only the proximal 179 bp of LH␤ promoter sequence but not induced after 6 h of GnRH agonist or TPA treatment (data not shown) was still repressed after 24 h of GnRH agonist or ionomycin (Fig. 6B) . The LH␤ promoter region from Ϫ146 bp to the mRNA start site was unable to mediate induction or repression of luciferase activity by GnRH (Fig. 6B and data not shown) despite containing the EGR-1, SF-1, and Ptx-1 binding sites previously reported to participate in GnRH responses (39, 41, 52, 60) .
Although the sequence between Ϫ179 and Ϫ146 of the rat LH␤ 5Ј flanking region has not been shown to bind specific proteins, Kaiser et al. (51) have noted the presence of a putative AP-1 binding site (TGAGACA, a six of seven match to the AP-1 consensus of TGA C / G TCA). To investigate whether this site is involved in the repression of LH␤ by GnRH or ionomycin after 24 h, we created a mutation in the putative AP-1 site of the Ϫ179 truncated LH␤ promoter (Ϫ179M), as described in Materials and Methods. It has been previously shown by EMSA that the equivalent CA to TG 2-bp mutation completely eliminates the binding of AP-1 complexes to an AP-1 consensus site (61) . As shown in Fig. 6B , this mutation eliminated repression of luciferase activity caused by GnRH cells were transiently transfected with 3 g Ϫ1800LH␤-Luc reporter plasmid and 1 g TK-CAT plasmid as an internal control, using FuGENE 6 transfection reagent. Sixteen hours after transfection, cells were treated with U0126 (750 nM) with or without GnRH agonist at 10 nM (A) or 1 nM (B), ionomycin (500 nM), or TPA (100 nM) for 6 h (A) or 24 h (B) before harvest. The value of the untreated sample for each time point was set to 100 to allow direct comparison of the magnitude of the GnRH induction. Results are the mean Ϯ SEM of three independent experiments, each performed in duplicate. Asterisks (*) indicate a significant difference, compared with the untreated cells. C, L␤T4 cells were serum starved overnight and then pretreated with 720 nM U0126 or DMSO vehicle for 30 min and stimulated with 0, 1, 10, or 100 nM GnRH for 5 min at 37 C. Whole-cell extracts were separated by SDS-PAGE and immunoblotted with an antibody to phospho-ERK1/2 (top panel). The blots were stripped and reblotted for ERK1/2 protein, demonstrating equivalent loading (bottom panel).
or ionomycin, suggesting the importance of the mutated bases for repression of LH␤ by GnRH or ionomycin.
Long-term repression of LH␤ transcription is not mediated by AP-1 binding
To determine whether AP-1 mediates LH␤ repression by GnRH through this binding site, we performed EMSA using an oligonucleotide probe representing the sequence from Ϫ163 to Ϫ142 of the LH␤ promoter, which contains the putative AP-1 element (51). We performed competition assays with 10-, 50-, 100-, or 200-fold excess of nonradioactive oligonucleotides: self (Ϫ163), a mutated oligonucleotide (Ϫ163M) altered in the same two base pairs as mutated in the transfections in Fig. 6 (see Ϫ179M) , and with an AP-1 consensus oligonucleotide described in Materials and Methods (Fig. 7) . As expected, addition of the unlabeled self-competitor at 100-and 200-fold excess completely abolished the major band binding to the radiolabeled probe (arrow, Fig. 7 ), but the faster migrating doublet was not well self-competed and is likely to be nonspecific binding. The addition of the Ϫ163M competitor resulted in a decrease of the major band, but substantial binding to the probe remained. Interestingly, the oligonucleotide containing an AP-1 consensus-binding site did not compete with the binding of the complex to the radiolabeled Ϫ163 probe. Therefore, although this binding complex uses at least part of the putative AP-1 site (the 2 bp mutated in Ϫ163M), it is not likely to be AP-1.
To further establish whether the protein complex that binds to the Ϫ163 to Ϫ142 region of the LH␤ promoter is AP-1, we performed EMSA using a labeled probe containing the AP-1 consensus site and incubated with a c-Fos antibody (Santa Cruz Biotechnology, Santa Cruz, CA) to detect the c-Fos protein, which is a component of the AP-1 complex. We saw an increase of binding intensity of one of the complexes (the upper band of the doublet, arrow, Fig. 8A ) after cells were treated with GnRH for 6 h, and formation of this complex was blocked by incubation with c-Fos antibody but not with IgG (Fig. 8A) . On the other hand, when the Ϫ163 to Ϫ142 oligonucleotide was used as a probe, we did not observe any changes in the binding intensity in the extracts from cells treated with GnRH for 6 h, compared with extracts from untreated cells (data not shown), and the c-Fos antibody did not have any effect on the protein complex that binds to the Ϫ163 to Ϫ142 oligonucleotide (Fig. 8B) . Finally, the AP-1 complex did not comigrate with the complex bound to the Ϫ163 probe (data not shown). These data further show that AP-1 does not bind to the element mediating repression of the LH␤ promoter by GnRH agonist or ionomycin.
If this complex is involved in repression by chronic GnRH or calcium, nuclear extracts isolated from cells treated with GnRH agonist or ionomycin might reveal changes in the intensity or migration of the complex. However, no changes in the binding pattern were observed between the untreated cells and cells treated with either GnRH or ionomycin after 6 h or 24 h (data not shown). The absence of differences in binding intensity after 6-or 24-h treatment suggests that the protein or protein complex bound to the Ϫ163 probe may mediate the repression, not by direct changes in its binding to the DNA, but rather by modification of the protein that is already bound to the DNA or, alternatively, by recruitment of other cofactors or corepressors.
To further characterize the complex binding to the Ϫ163 probe, we performed competition assays with an excess of the unlabeled Ϫ163 oligonucleotide containing a variety of mutations. The oligonucleotides used for the competition analysis are shown in Fig. 9A . The mutated bases are shown in bold and the 2-bp mutation used in transfection analysis and in Fig. 7 is underlined. As shown in Fig. 9B , addition of 100-fold excess of the oligonucleotide containing a mutation eliminating the AP-1 binding site (M1) still completely abolished binding to the radiolabeled probe, again supporting the conclusion that the major complex does not contain AP-1. However, the mutations downstream of M1 either partially decreased or did not change, the intensity of the protein binding to the radiolabeled probe indicating that these competitors do not bind the complex. From these data, it seems likely that the binding site for this protein is downstream of the putative AP-1 site in the sequence ACACTGGAGCT from Ϫ153 to Ϫ143. Next, we determined the level of conservation of this site across species. The comparison of rat LH (rLH), mouse LH, human LH (hLH), and equine LH (eLH) LH␤ 5Ј flanking regions shows that the ACTG(A/G)NNCT sequence is conserved among these four species (Fig. 10A) . Searches in the TRANSFAC transcription factor database (http://transfac. gbf.de/TRANSFAC/) did not produce any likely candidates for this DNA-binding protein. An equivalent EMSA complex was present using extracts from the L␤T4, ␣T3-1, ␣T1-1 (62), HeLa, and NIH3T3 cell lines, showing that it is not specific to the gonadotrope lineage (data not shown).
It has been previously shown that naturally occurring mutations (63) in the human LH␤ promoter sequence (variant LH, VLH) result in higher expression of the human LH␤ reporter gene in both L␤T2 and human embryonic kidney 293 cell lines, and one of these mutations is in the putative AP-1 site of the human LH␤ promoter in a nucleotide (equivalent to Ϫ147 in the rat) that would also affect the binding of the complex bound to the downstream repression element (64) . In the VLH gene, this nucleotide is the same as the rat and mouse (G), but in human and equine it is different (A; boxed in Fig. 10A ). When we performed EMSA using hLH, VLH, or eLH oligonucleotides as the radiolabeled probes, we found that all of these probes bound a complex that comigrated with the complex bound to the rLH (Ϫ163) probe (Fig.  10B) . Moreover, cross-competition assays showed that all of these oligonucleotides fully cross-compete with each other, indicating that they bind the same protein.
Discussion
Long-term treatment with GnRH agonists in patients with gonadal-steroid sensitive cancers produces a profound repression of the pituitary gonadotropins resulting in suppression of gonadal steroid production (65) . The power of GnRH to induce LH gene expression in the short term then repress it below basal levels after chronic treatment is particularly intriguing and provides an opportunity for understanding the signaling mechanisms used by GnRH in temporal control of gonadotropin gene expression.
In this article, we have addressed the difference between acute and chronic treatment with GnRH on the regulation of LH␤ gene transcription in L␤T4 cells, an immortalized mouse gonadotrope cell line. Our results suggest that there are at least two signaling systems downstream of GnRH-R in the L␤T4 cells. One system is activated through PKC and is responsible for acute induction of LH␤ transcription. Another system is activated through calcium-signaling pathways independent of PKC and is responsible for intense down-regulation of LH␤ transcription. At early time points, the PKC system is more potent, and therefore transcription of the LH␤ gene is induced. After long-term treatment, when the PKC system exhausts, the calcium system predominates (or the combination of these two effects occurs), resulting in down-regulation of the LH␤ gene.
We observed that repression of LH␤ gene transcription after 24-h incubation with GnRH was sensitive to the dose of GnRH agonist used. The reversal of repression at the higher doses may be due to desensitization and/or down-regula- tion of the GnRH-R, preventing chronic signaling. Cheng et al. (66) have shown that in ␣T3-1 cells, incubation with 100 nm GnRH agonist for 24 h leads to repression of GnRH receptor promoter activity. In GGH 3 cells, in which transcription of the GnRH-R is driven by a heterologous promoter and thus likely to be refractory to GnRH, high doses of Buserelin down-regulate the G q/11 ␣ protein involved in GnRH signaling (67) . A higher dose (10 nm), although failing to repress, also failed to induce the LH␤ gene at 24 h, indicating that the induction produced by this dose at 6 h is lost by 24 h.
To delineate the signaling cascades downstream of the GnRH-R that are used in induction vs. repression, we studied the effects of direct activation or inhibition of the calcium, kinase C, and MAPK pathways. Activation of LH␤ transcription after 6-h incubation with the PKC activator TPA ( Fig. 2A) and the loss of induction by GnRH in the 6 h coincubation with the PKC inhibitor BMM (Fig. 4A) show that acute induction of LH␤ transcription occurs through the PKC system. The absence of any induction at 6 h with the calcium ionophore, ionomycin ( Fig. 2A) , supports the conclusion that calcium is not involved in acute transcriptional induction of the LH␤ gene by GnRH. Moreover, LH␤ is still induced by GnRH or TPA in the presence of the calcium chelator, EGTA (Fig. 3B) .
Previous reports on the role of the MAPK pathway in the induction of LH␤ by GnRH are controversial. Haisenleder et al. (68) , using primary pituitary cultures, have shown that the inhibition of MEK abolished the GnRH induction of ␣-subunit, GnRH-R, and FSH␤ but not of LH␤. Furthermore, overexpression of dominant negative MAPKs was sufficient to repress GnRH induction of mouse ␣-subunit (69, 70) . On the other hand, Wolfe et al. (71) and Weck et al. (23) , using the ␣T3-1 cell model, showed that MAPK is involved in the induction of LH␤ gene transcription by GnRH in this non-LH␤-expressing cell type. In our experiments, inhibition of the MAPK system with U0126 does not change either induction by GnRH or TPA after 6 h of treatment or the repression by GnRH or ionomycin after 24 h of treatment. These results demonstrate that in the L␤T4 cell model, the MAPK system is not involved in either the acute induction or the chronic repression of the LH␤ 5Ј regulatory region.
GnRH-R activation leads to an increased concentration of intracellular calcium. It has been shown that this increase is due to two events: calcium channel opening and calcium release from intracellular stores (11) . We have found that chronic GnRH represses LH␤ transcription through the calcium system. Although GnRH, TPA, and ionomycin can all repress LH␤ gene expression at 24 h, only the calcium chelator, EGTA (but not the MAPK or kinase C inhibitors), blocks the effect of GnRH after the 24-h incubation.
Two observations support a role for calcium as a negative regulator of LH␤ at the earlier 6-h treatment time point as well. Blockade of calcium by EGTA augments both GnRH and TPA induction at 6 h (Fig. 3A) , indicating an existing downward pressure on LH␤ transcription at 6 h by calcium. Furthermore, when ionomycin is coadministered with the kinase C inhibitor, BMM, at the 6-h time point (Fig. 4A) , repression of the LH␤ gene below basal levels becomes evident. These data suggest that the calcium system is responsible for repression at earlier time points but that it is not sufficient to overcome the acute activation of LH␤ gene expression by the PKC system. However, GnRH does not repress LH␤ at the 6-h time point when given in combination with BMM. GnRH may not be as potent an activator of the calcium system as ionomycin. However, later, after the 24-h treatment, PKC activity is exhausted, so that repression of LH␤ transcription can be observed after 24 h of incubation with a GnRH agonist or TPA.
Induction of the kinase C system, although not required for chronic GnRH repression, can also cause repression of LH␤ gene expression in that 24 h of TPA treatment downregulates the LH␤ gene. TPA is known to cause degradation of some kinase C isoforms after 24 h and this may contribute to the decrease in LH␤ gene expression. Cross-talk between these two systems makes it possible that PKC activates the calcium system before the PKC system is down-regulated, resulting in the same outcome (repression of LH␤) as chronic GnRH or ionomycin treatment. This possibility of cross-talk may also explain why the 24-h treatment with EGTA partially blocks the repression caused by TPA (Fig. 3B) .
GnRH stimulation plays a crucial role in the regulation of the molecular markers of the gonadotrope lineage, such as ␣-subunit, LH␤, FSH␤, and GnRH-R. Regulation of ␣-subunit transcription is relatively well studied. It has been shown that GnRH regulation of the transcription of ␣-subunit is species specific and is gradual, requiring longer incubation with tonic GnRH. In rodents, this regulation occurs through activation of ETS elements (52, 72) , and in humans, cAMP response elements are involved (73) . Studies The boxed nucleotides are those mutated in the VLH vs. hLH genes. B, Radioactive-labeled probe (3 fm) and 100-fold molar excess of unlabeled competitor were added simultaneously to either nuclear extract from untreated L␤T4 cells or nuclear extract from L␤T4 cells treated with GnRH for 24 h. In lanes 1-5, the rLH oligonucleotide was used as probe; in lanes 6 -10, the hLH oligonucleotide was used as probe; in lanes 11-15, the VLH oligonucleotide was used as probe; and in lanes 16 -20, the eLH oligonucleotide was used as probe. Lanes 1, 6, 11, and 16 had no competitor; lanes 2, 7, 12, and 17 had the Ϫ163 oligonucleotide as a competitor; lanes 3, 8, 13, and 18 had the hLH oligonucleotide as a competitor; lanes 4, 9, 14, and 19 had the VLH oligonucleotide as a competitor; lanes 5, 10, 15, and 20 had the eLH oligonucleotide as a competitor.
using ␣T3-1 cells show that GnRH up-regulates the mouse GnRH-R gene through the PKC system at an AP-1 site (74) . Another study that also used ␣T3-1 cells identified two elements, called SURGE-1 and SURGE-2, that mediate the induction of mouse GnRH-R gene transcription by GnRH. SURGE-2 was identified as an AP-1 site (75) .
Several transcription factors, tissue specific as well as ubiquitous, bind to the LH␤ promoter. In GGH 3 cells, two regions of the rat LH␤ promoter are important for induction by GnRH (51) . The distal region, termed region A (Ϫ451 to Ϫ386 bp), contains several SP-1 binding sites and is capable of binding SP-1 (31) . In addition to SP-1 sites, this region has been shown to have CArG elements important for GnRH induction in L␤T2 cells (52) . GnRH action through the proximal region, spanning from Ϫ207 bp downstream, was shown to require EGR-1 binding sites in both GGH 3 (51) and L␤T2 cells (52, 76) . Other tissue-specific proteins, such as SF-1 and Ptx-1, also have binding sites in the proximal region. In cotransfections into CV-1 or JEG-3 cells, it has been shown that SF-1, Ptx-1, and EGR-1 interact to increase the activity of the LH␤ promoter (39, 41, 60) and mutation of an EGR site inhibits GnRH induction in L␤T2 cells (41, 52, 60) . This region also contains putative sites for AP-1 (seven of eight of consensus site) and cAMP response element-binding protein (six of eight of consensus) (51) .
Our experiments (Fig. 6, A and B) show not only that the PKC and calcium systems act on different regions of the LH␤ promoter, but they also provide insight into the protein(s) that may be responsible for induction vs. repression of LH␤ by GnRH. It is likely that GnRH induces activity of the LH␤ promoter in L␤T4 cells through CArG-1 and SP-1 sites, located in region A. Despite the fact that SP-1 is a ubiquitous protein, the localization of GnRH-R to the gonadotrope may be sufficient to provide cell-specific regulation of LH␤ by GnRH. On the other hand, the possibility cannot be excluded that an EGR-1/SF-1/Ptx-1 complex is also necessary for LH␤ induction by GnRH and that it interacts with SP-1. Weck et al. (52) showed that mutation of the CArG box or the proximal SP-1 site completely abolishes the induction of the LH␤ promoter by GnRH in L␤T2 cells, thus supporting the hypothesis of the interaction between the transcription factors binding to region A and region B. Interestingly, however, the authors of that study were not able to show induction of LH␤ by continuous stimulation with GnRH after 8 h, but in our study GnRH is capable of LH␤ induction after 6 h of tonic treatment. It is likely that GnRH induces LH␤ gene expression after 6 h of tonic treatment, but in their study this induction had disappeared by 8 h.
We have also shown that the LH␤ promoter region from Ϫ179 to Ϫ146 is necessary for repression of the LH␤ gene by GnRH. The SF-1, EGR-1, and Ptx-1 sites are all located more proximal within Ϫ127 of the rat LH␤ promoter. EMSAs show that the region involved in repression of the LH␤ promoter binds a protein that overlaps a nonconsensus AP-1 site but is not AP-1. A similar site is present in the LH␤ promoters of other species, and the fact that the eLH, hLH, and VLH probes all bind the same complex suggests that this protein may play a conserved role in the regulation of LH␤ gene expression.
The human GnRH-R gene has been shown to be downregulated after transfection into ␣T3-1 cells by a wide range of GnRH doses as early as 6 h but maximal at 24 h with 100 nm (66) . In contrast to repression of the LH␤ gene by GnRH, this repression is mediated by the PKC system in that TPA treatment reproduces the repression and inhibition of the PKC system prevents GnRH repression. Mutation of an AP-1 site at Ϫ1000 abolishes the repression and AP-1 was found to bind this element and be induced by 100 nm GnRH at 24 h. This AP-1 site is not the same as the one found in the proximal promoter of the mouse GnRH-R gene responsible for induction (74, 75) . Thus, although AP-1 may be involved in repression of the human GnRH-R gene, it is not responsible for repression of the rat LH␤ gene. It is clear that the signaling cascades activated by GnRH are diverse, employing a variety of different transcription factors to differentially induce or repress the expression of key genes expressed in the gonadotrope. In the case of the LH␤ gene, GnRH activation of the PKC cascade is required for acute induction, but this cascade acts independently of downstream MAPK activation and does not require calcium influx. In contrast, repression of the LH␤ gene by GnRH occurs through the calcium signaling system, again independently of MAPK but also independently of PKC. Not only does GnRH use different signaling systems to induce, as opposed to repress, LH␤ gene expression, but it also uses different elements within the gene for induction vs. repression of LH␤ gene expression.
